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To the Editor, 33 
Wheezing is a common symptom during viral respiratory tract infections in children aged less 34 
than 24 months, but the distinction between wheezing and asthma is difficult, because 35 
diagnostic tests are not available.1 Empiric drug therapy with inhaled corticosteroids (ICS) 36 
has been recommended, particularly if the symptom pattern is consistent with asthma or if 37 
there is a considerable burden of symptoms.1  38 
Treatment with an ICS has potential adverse effects such as impaired linear growth.1-3 39 
Several studies of children older than 2 years have shown that these growth effects are dose-40 
dependent albeit relatively small.2,3 In addition, only one study has reported compromised 41 
adult height after ICS exposure.4 Studies for children aged less than 24 months remain 42 
scarce.2-3 In a small study Bisgaard et al. reported no adverse growth effects.5 However, 43 
further studies are clearly needed as  the Prevention of Early Asthma in Kids (PEAK) Study 44 
and its post hoc analysis reported significant growth reduction without catch-up after 45 
medication discontinuation in a subgroup of children aged 2 years at the initiation of 46 
fluticasone propionate (FP).6,7   47 
We evaluated the effects of ICS exposure prior to 24 months of age on linear growth in a 48 
Finnish population-based cohort of 12,482 children, who were carefully screened for chronic 49 
conditions and other factors that could affect growth (see Fig E1 and Table E21 in this 50 
article's Online Repository at www.jacionline.org). The first height and weight measurements 51 
at or after 24 months of age were used as primary end-points (median age 25 months 52 
[interquartile range 24 to 26 months]). Our hypothesis was that ICS use during the first 24 53 
months of life compromises linear growth, and the effect varies by the dose and the duration 54 
of ICS treatment.  55 
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Based on information from the Drug Purchase Register covering all prescribed and 56 
reimbursed drug purchases in Finland, 562 of 12,482 (4.5%) children had been exposed to 57 
ICS (2.0% to budesonide [BUD], 2.3% to FP and 0.2% to both) and 424 (3.4%) to other anti-58 
asthmatic drugs (monteluk -sympathomimetic drugs, or oral corticosteroids) 59 
before the age of 24 months. Children with ICS exposure were classified into nine groups 60 
according to the daily ICS doses (a minimal, a low or a medium/high dose in comparison to 61 
the recommended daily dose)1 and the duration of the treatment (< 3 months, 3 - 6 months 62 
and > 6 months) (Table E1). Linear growth was compared between the exposed and 63 
unexposed groups using two growth parameters: height-for-age z-score (zHFA)9 and zHFA 64 
deviation from target height z-score based on parental heights (zTHDEV).9 Statistical 65 
comparison was performed using covariance analysis with random effects (See 66 
the Online Repository at www.jacionline.org.)       67 
Children exposed to ICS were significantly shorter than unexposed children at the median 68 
age of 25 months The mean adjusted differences in zHFA and zTHDEV were -0.13 (95% CI -69 
0.18 to -0.08) and -0.15 (95% CI -0.20 to -0.10) as compared to unexposed children (Table 70 
1).  71 
Daily low dose ICS consumption was associated with a growth-suppressing effect at or after 72 
24 months of age if the medication was used more than 6 months (Fig 1). The mean zTHDEV 73 
difference from the unexposed children was -0.25 (95% CI -0.41 to -0.09). However, after 74 
treatment with medium/high dose ICS for 3 - 6 months, or > 6 months, reduction in average 75 
height was even more pronounced. The mean zTHDEV differences between exposed and 76 
unexposed children were -0.53 (95% CI -0.79 to  -0.26) and -0.25 (95% CI -0.46 to -0.03), 77 
respectively, equaling to up to 1 cm loss in height at or after 24 months of age in both sexes.  78 
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In this population-based study, we show that ICS exposure during the infancy is 79 
independently associated with poor linear growth at or after 24 months of age.  Young 80 
children that were exposed to daily low dose ICS therapy for >6 months had significant 81 
reduction in height in comparison to unexposed children. However, neither daily minimal 82 
dose nor short term (< 3 months) use of ICS even at a medium/high dose were not associated 83 
with attenuated growth. Nevertheless, individual responses to ICSs may vary considerably. 84 
Our observations confirm and complement the findings of Guilbert et al,7 indicating that 85 
infants are more susceptible to growth-impairing effects of ICSs than children after 24 86 
months of age. Infancy is characterized by rapid linear growth, which is vulnerable to 87 
suboptimal environmental effects. A positive secular change in adult height has been 88 
attributed primarily to improved environmental conditions in infancy, which facilitates the 89 
use of full growth potential during that period.9 Factors interfering with physical development 90 
during infancy likely cause long-term effects on later growth.9 Growth attenuation in early 91 
life is not always followed by catch-up, as shown in the PEAK-Study7 wherein children aged 92 
2 years did not exhibit catch-up growth after cessation of the medication, although older 93 
children did. In this study we could not access longitudinal growth data beyond the age of 25 94 
months and therefore catch-up growth in our cohort of exposed children remains unknown. 95 
The major strength of our study was the large, carefully examined population-based cohort of 96 
infants and their longitudinal growth data sets, as well as parental height data. These data 97 
enabled the comparison of the linear growth against the individual genetic growth potential. 98 
We also utilized the national drug purchase register as a source of medication data, which 99 
likely is a more reliable source than prescription data or information based on self-reported 100 
use. Due to the retrospective nature of our data we cannot, however, provide conclusive 101 
causality between ICS and growth. 102 
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In summary, ICS exposure before 24 months of age is associated with attenuated linear 103 
growth. Careful considerations should be given to developing treatment modalities that are 104 
safe including formulations of ICS and devices for their administration for young children. 105 
Further studies on efficacy and safety of ICS in infants are clearly needed.6,7 Meanwhile, 106 
judicious use of ICS in infants is warranted, and during  ICS treatment linear growth of 107 
children should be frequently and carefully monitored. 108 
 109 
Yours sincerely, 110 
Antti Saari*, MD, PhD, Kuopio University Hospital, Kuopio, Finland 111 
Lauri J. Virta*, MD, PhD, Social Insurance Institution of Finland, Turku, Finland 112 
Leo Dunkel, MD, PhD, William Harvey Research Institute, Barts and the London, Queen 113 
Mary University of London, London, United Kingdom 114 
Ulla Sankilampi, MD, PhD, Kuopio University Hospital, Kuopio, Finland 115 
 116 
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Figure 1 Association of the dose of inhaled corticosteroid (ICS) and duration of ICS 142 
treatment with the height-for-age z-score deviation from target height (zTHDEV) at or after 24 143 
months of age. Bars indicate the adjusted mean differences with 95% confidence intervals in 144 
comparison to unexposed children (the zero line). 145 
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Permission for the study was obtained from Espoo Municipality Institutional Review Board, 4 
The Social Insurance Institution of Finland (SII), and the National Institutes of Health and 5 
Welfare (THL). Analyses were performed with encrypted register data. 6 
Study Population 7 
The Finnish child welfare clinics in primary care provide pre-scheduled visits (monthly from 8 
birth to 6 months, 8, 12, 18, and 24 months of age, then annually) to all children living in 9 
Finland, with a coverage of nearly 100% of the child population.E1,E2 These visits include 10 
auxological evaluation (length/height, and weight) by specially trained nurses with 11 
standardized equipment.E1,E2 For this study, we initially included all 14,764 children born 12 
between January 1, 2003, and April 30th 2007 (51% boys) who attended child welfare clinics 13 
in the city of Espoo, Finland, and had at least one visit at or after 24 months (Figure E1).E3  14 
To exclude children with prenatal conditions affecting growth, and to control for possible 15 
confounding perinatal factors statistically, we obtained the Medical Birth Register data from 16 
the Finnish National Institute of Health and Welfare.E4 These data included maternal age, 17 
smoking during pregnancy, parental relationship, gestational age, mode of delivery, parity, 18 
plurality, birth weight and length, season at birth, and congenital syndromes or anomalies. 19 
First, we excluded 1,381 children with any of the following: preterm birth at <37 gestational 20 
weeks, congenital anomaly or syndrome, and a lack of perinatal data.  Second, we excluded 21 




growth (not ICS or other anti-asthmatic drugs) (N = 901). The final study population was 23 
comprised of 12,482 children, while 6,391 (51%) of them were boys (Figure E1).  24 
Auxological data and growth outcomes 25 
All of the available growth data from birth to the age over 24 months, as well as data on 26 
parental heights were collected from the electronic health records of child welfare clinics in 27 
primary care. Potentially false measurements or typing errors were evaluated by scatter plots, 28 
and either corrected or excluded. Birth size, length and weight measurements, and body mass 29 
indices (BMI, calculated as weight [kg]/height [m]2)] were transformed into z-scores (BMI-30 
for-age, weight-for-length, and height-for-age) according to contemporary Finnish growth 31 
references.E3,E5 Target height (TH) was calculated by using parental heights,E6 and height-for-32 
age z-score deviation from TH z-score was expressed as zTHDEV.  33 
Exposure to inhaled corticosteroids  34 
In Finland, ICS and other medications for recurrent wheezing/asthma are available only by 35 
prescription and sold in registered pharmacies. Two types of ICS, budesonide (BUD) and 36 
fluticasone propionate (FP) are licensed by the Finish Medicines Agency (Fimea) for daily 37 
use in infancy from the age of 6 months (BUD) and 12 months (FP). In the case of recurrent 38 
wheezing, off-label ICS have been prescribed for patients younger than 6 months. 39 
Formulations applicable for infants included metered-dose inhalers delivered by a spacer 40 
(BUD, FP) or inhaled suspension delivered by a nebulizer (BUD).E7  41 
The Drug Purchase Register covers all drug purchases prescribed by physicians and 42 
reimbursed by the National Sickness Insurance Scheme in Finland. The register data include 43 
information on drug class, quantity, and date of dispense.E8 Drugs are categorized according 44 
to the Anatomical Therapeutic Chemical (ATC) Classification System, developed by the 45 
World Health Organization (WHO) for drug consumption statistics.E9 Information about the 46 
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purchase of drugs for asthma (ATC- -sympathomimetics, 47 
montelukast), systemic corticosteroids (H02AB), and systemic antibiotics (J01) was merged 48 
to the growth data. According to the annual wholesale survey conducted by the Fimea, the 49 
Drug Purchase Register of SII has a coverage of about 93% of all outpatient consumption of 50 
drugs for obstructive airway diseases (R03). Medications administrated in hospitals were not 51 
collected.  52 
Altogether 562 (4.5%) children of the study population had been exposed to ICS before the 53 
age of 24 months (Table E1). ICS was delivered by a spacer (BUD [N=227, 93%], FP 54 
[N=283, 100%]) or by a nebulizer (BUD [N=17, 7%]). Detailed information of the spacer 55 
devices was not available in The Drug Purchase Register. In addition, 424 children (3.4%) 56 
had been exposed to anti-asthmatic drugs other than ICS (montelukast -57 
sympathomimetic drugs, or oral corticosteroids). The reference population without exposure 58 
to any of these drugs consisted of 11,496 children (Fig E1). 59 
Duration of the treatment and the average daily dose of ICS for each individual child was 60 
calculated using the Drug purchase register data on the type and number of ICS purchases 61 
before the age of 24 months. The Finnish regulations allow for the purchase of reimbursed 62 
medication for the period of 3 months. Duration of the ICS treatment for an individual child 63 
was calculated using the total number of the purchases prior to 24 months of age (one 64 
purchase = treatment < 3 months, two purchases = treatment 3 - 6 months, three or more 65 
purchases = treatment >6 months). In addition, the purchased doses of ICSs were divided by 66 
the number of days between the first and the following purchases stepwise until the growth 67 
visit at or after 24 months of age resulting into the average daily dose of a child. The average 68 
daily dose of ICS was then categorized as a medium/high dose (equal or more than daily 69 
BUD 400 µg or FP 200 µg via spacer, or BUD 1000 µg via nebulizer),  a low-dose (half of 70 
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the medium dose), and a minimal dose (equal or less than one quarter of the medium dose), 71 
according to the Global Initiative for Asthma report.E10  72 
Statistical analyses 73 
Frequency of perinatal factors and postnatal factors possibly interfering with growth in 74 
infancy, or affecting exposure to ICS (Table E2) was compared with the chi square test. 75 
Baseline growth data (height-for-age, weight-for-length z-score and zTHDEV) of the ICS 76 
exposed and unexposed infants (closest measurements to ICS initiation in the unexposed 77 
infants at median age of ICS initiation, i.e., at 12 months) were compared using independent 78 
sample t-tests for normally distributed parameters (Table E3). Variables achieving statistical 79 
significance (p < 0.05) in the model were selected for adjusted growth analyses. 80 
The linear growth at 24 months or closest to that age; median age at measurement, 25 81 
months, (IQR from 24 to 26 months) was compared between children exposed to ICS, 82 
exposed to other anti-asthmatic medications, and unexposed children using covariance 83 
analysis with random effects for subjects. Mean differences of zTHDEV between the exposure 84 
groups were assessed in relation to exposure to any ICS (yes/no), or to the average daily dose 85 
of ICS  (minimal, low or  medium/high dose) and duration of treatment (< 3 months, 3 - 6 86 
months, > 6 months) (Table E3) . 87 
Data were analyzed using SPSS software (version 21, IBM Corporation, Armonk, NY, USA). 88 
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Permission for the study was obtained from Espoo Municipality Institutional Review Board, 4 
The Social Insurance Institution of Finland (SII), and the National Institutes of Health and 5 
Welfare (THL). Analyses were performed with encrypted register data. 6 
Study Population 7 
The Finnish child welfare clinics in primary care provide pre-scheduled visits (monthly from 8 
birth to 6 months, 8, 12, 18, and 24 months of age, then annually) to all children living in 9 
Finland, with a coverage of nearly 100% of the child population.E1,E2 These visits include 10 
auxological evaluation (length/height, and weight) by specially trained nurses with 11 
standardized equipment.E1,E2 For this study, we initially included all 14,764 children born 12 
between January 1, 2003, and April 30th 2007 (51% boys) who attended child welfare clinics 13 
in the city of Espoo, Finland, and had at least one visit at or after 24 months (Fig E1).E3  14 
To exclude children with prenatal conditions affecting growth, and to control for possible 15 
confounding perinatal factors statistically, we obtained the Medical Birth Register data from 16 
the Finnish National Institute of Health and Welfare.E4 These data included maternal age, 17 
smoking during pregnancy, parental relationship, gestational age, mode of delivery, parity, 18 
plurality, birth weight and length, season at birth, and congenital syndromes or anomalies. 19 
First, we excluded 1,381 children with any of the following: preterm birth at <37 gestational 20 
weeks, congenital anomaly or syndrome, and a lack of perinatal data.  Second, we excluded 21 




growth (not ICS or other anti-asthmatic drugs) (N = 901). The final study population was 23 
comprised of 12,482 children, while 6,391 (51%) of them were boys (Figure E1).  24 
Auxological data and growth outcomes 25 
All of the available growth data from birth to the age over 24 months, as well as data on 26 
parental heights were collected from the electronic health records of child welfare clinics in 27 
primary care. Potentially false measurements or typing errors were evaluated by scatter plots, 28 
and either corrected or excluded. Birth size, length and weight measurements, and body mass 29 
indices (BMI, calculated as weight [kg]/height [m]2)] were transformed into z-scores (BMI-30 
for-age, weight-for-length, and height-for-age) according to contemporary Finnish growth 31 
references.E3,E5 Target height (TH) was calculated by using parental heights,E6 and height-for-32 
age z-score deviation from TH z-score was expressed as zTHDEV.  33 
Exposure to inhaled corticosteroids  34 
In Finland, ICS and other medications for recurrent wheezing/asthma are available only by 35 
prescription and sold in registered pharmacies. Two types of ICS, budesonide (BUD) and 36 
fluticasone propionate (FP) are licensed by the Finish Medicines Agency (Fimea) for daily 37 
use in infancy from the age of 6 months (BUD) and 12 months (FP). In the case of recurrent 38 
wheezing, off-label ICS have been prescribed for patients younger than 6 months. 39 
Formulations applicable for infants included metered-dose inhalers delivered by a spacer 40 
(BUD, FP) or inhaled suspension delivered by a nebulizer (BUD).E7  41 
The Drug Purchase Register covers all drug purchases prescribed by physicians and 42 
reimbursed by the National Sickness Insurance Scheme in Finland. The register data include 43 
information on drug class, quantity, and date of dispense.E8 Drugs are categorized according 44 
to the Anatomical Therapeutic Chemical (ATC) Classification System, developed by the 45 
World Health Organization (WHO) for drug consumption statistics.E9 Information about the 46 
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purchase of drugs for asthma (ATC- -sympathomimetics, 47 
montelukast), systemic corticosteroids (H02AB), and systemic antibiotics (J01) was merged 48 
to the growth data. According to the annual wholesale survey conducted by the Fimea, the 49 
Drug Purchase Register of SII has coverage of about 93% of all outpatient consumption of 50 
drugs for obstructive airway diseases (R03). Medications administrated in hospitals were not 51 
collected.  52 
Altogether 562 (4.5%) children of the study population had been exposed to ICS before the 53 
age of 24 months (Table E1). ICS was delivered by a spacer (BUD [N=227, 93%], FP 54 
[N=283, 100%]) or by a nebulizer (BUD [N=17, 7%]). Detailed information of the spacer 55 
devices was not available in The Drug Purchase Register. In addition, 424 children (3.4%) 56 
had been exposed to anti-asthmatic drugs other than ICS (montelukast -57 
sympathomimetic drugs, or oral corticosteroids). The reference population without exposure 58 
to any of these drugs consisted of 11,496 children (Figure E1). 59 
Duration of the treatment and the average daily dose of ICS for each individual child was 60 
calculated using the Drug purchase register data on the type and number of ICS purchases 61 
before the age of 24 months. The Finnish regulations allow for the purchase of reimbursed 62 
medication for the period of 3 months. Duration of the ICS treatment for an individual child 63 
was calculated using the total number of the purchases prior to 24 months of age (one 64 
purchase = treatment < 3 months, two purchases = treatment 3 - 6 months, three or more 65 
purchases = treatment >6 months). In addition, the purchased doses of ICSs were divided by 66 
the number of days between the first and the following purchases stepwise until the growth 67 
visit at or after 24 months of age resulting into the average daily dose of a child. The average 68 
daily dose of ICS was then categorized as a medium/high dose (equal or more than daily 69 
BUD 400 µg or FP 200 µg via spacer, or BUD 1000 µg via nebulizer),  a low-dose (half of 70 
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the medium dose), and a minimal dose (equal or less than one quarter of the medium dose), 71 
according to the Global Initiative for Asthma report.E10  72 
Statistical analyses 73 
Frequency of perinatal factors and postnatal factors possibly interfering with growth in 74 
infancy, or affecting exposure to ICS (Table E2) was compared with the chi square test. 75 
Baseline growth data (height-for-age, weight-for-length z-score and zTHDEV) of the ICS 76 
exposed and unexposed infants (closest measurements to ICS initiation in the unexposed 77 
infants at median age of ICS initiation, i.e., at 12 months) were compared using independent 78 
sample t-tests for normally distributed parameters (Table E3). Variables achieving statistical 79 
significance (p < 0.05) in the model were selected for adjusted growth analyses. 80 
The linear growth at 24 months or closest to that age; median age at measurement, 25 81 
months, (IQR from 24 to 26 months) was compared between children exposed to ICS, 82 
exposed to other anti-asthmatic medications, and unexposed children using covariance 83 
analysis with random effects for subjects. Mean differences of zTHDEV between the exposure 84 
groups were assessed in relation to exposure to any ICS (yes/no), or to the average daily dose 85 
of ICS  (minimal, low or  medium/high dose) and duration of treatment (< 3 months, 3 - 6 86 
months, > 6 months) (Table E3) . 87 
Data were analyzed using SPSS software (version 21, IBM Corporation, Armonk, NY, USA). 88 
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Initial study population: 
 Children born between 1st January 2003 and 30th 
April 2007, and with growth data from birth to at 
least 24 months of age 
 N = 14,764 (7,584 boys and 7,180 girls) 
N = 13,383 
Exclusion 1: 
 Gestational age < 37 wks, and/or 
 Congenital syndrome, and/or  
 Lack of perinatal data 
 1,381 children (9.4%) 
Exclusion 2: 
 Growth disorder and/or 
 Regular medication potentially 
affecting growth (not inhaled 
corticosteroids or other drugs 
for wheezing/asthma) 
 901 children (6.1%) 
Birth register data 
Medical records 
Final study population, N = 12,482 (6,391 boys and 6,091 girls): 
 11,496 healthy children (without exposure to inhaled corticosteroids, per oral 
-sympathomimetic drugs) 
 
 562 children with exposure to inhaled corticosteroids 
o 244 children with exposure to budesonide only 
o 283 children with exposure to fluticasone only 
o 35 children with exposure to both budesonide and fluticasone 
 
 424 children with exposure to other medications for wheezing/asthma (per 
-sympathomimetic drugs)  
 
N = 12,482 
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Table E1 Use of inhaled corticosteroids (ICS) and other asthma medications before 
the age of 24 months in the study population of 12,482 children.   
 Total 
n = 12,482 
(100%) 
Male 
n = 6,391 
(100%) 
Female 
n = 6,091 
(100%) 
p-valuea 
EXPOSURE TO ICS 562 (4.5) 375 (5.9) 187 (3.1) <0.001 
Average daily doseb and duration 
of the treatment 
Minimal dose 
    
<3 months 204 (1.6) 135 (2.1) 69 (1.1)  
3 - 6months 19 (0.2) 13 (0.2) 6 (0.1)  
 >6 months 27 (0.2) 21 (0.3) 6 (0.1)  
Low dose     
 <3 months 109 (0.9) 65 (1.0) 44 (0.7)  
3 - 6 months 59 (0.5) 38 (0.6) 21 (0.3)  
 >6 months 62 (0.5) 49 (0.8) 13 (0.2)  
Medium/high dose     
<3 months 28 (0.2) 19 (0.3) 9 (0.1)  
3 - 6months 22 (0.2) 13 (0.2) 9 (0.1)  
 >6 months 32 (0.2) 22 (0.3) 10 (0.2)  
EXPOSURE TO OTHER 
ASTHMA MEDICATIONS THAN 
ICSc 424 (3.4) 273 (4.3) 151 (2.5) <0.001 
NO EXPOSURE TO ANTI-
ASTHMATIC MEDICATION 11,496 (92.1) 5,743 (89.9) 5,753 (94.5) <0.001 
aComparison between males and females 
bThe average daily dose of ICS was defined as medium/high  (equal or more than daily BUD 400 µg 
or FP 200 µg via spacer, and BUD 1000 µg via nebulizer), as  low (half of the medium dose), or as 
minimal (equal or less than one quarter of the medium dose), according to the Global Initiative for 
Asthma report. E10 





Table E2 Background factors potentially associated with linear growth or with exposure to 
inhaled corticosteroids in infancy in the study population of 12,482 children 
 Height-for-age percentilea  Exposure to inhaled 
corticosteroids 
 
Column, count (%) <50th th p-value No Yes p-value 
Total count 6,382  6,100  11,920 562  
       
Gender     0.90     <0.001 
Male 3,264 (51.1) 3,127 (51.3)  6,016 (50.5) 375 (66.7)  
Female 3,118 (48.9) 2,973 (48.7)  5,904 (49.5) 187 (33.3)  
Exposure to oral 
corticosteroids 
    
0.42 
    
<0.001 
No 6,338 (99.3) 6,065 (99.4)  11,880 (99.7) 523 (93.1)  
Yes 44 (0.7) 35 (0.6)  40 (0.3) 39 (6.9)  
Exposure to 
antibiotics 
    
0.04     <0.001 
No 1,506 (23.6) 1,347 (22.1)  2,838 (23.8) 15 (2.7)  




<0.001   0.003 
No 5,416 (84.9) 4,872 (79.9)   9,851 (82.6) 437 (77.8)  
Yes 966 (15.1) 1,228 (20.1)  2,069 (17.4) 125 (22.2)  
Maternal age     0.60     0.67 
<30 years 2,607 (40.8) 2,520 (41.3)  4,901 (41.1) 226 (40.4)  
 3,775 (59.2) 3,580 (58.7)  7,019 (58.9) 336 (59.8)  
Maternal smoking     0.12     0.50 
No 5,760 (90.3) 5,555 (91.1)  10,801 (90.6) 514 (91.5)  
Yes 622 (9.7) 545 (8.9)  1,119 (9.4) 48 (8.5)  
Maternal 
relationship 
    
0.88     0.02 
Partner 5,977 (93.7) 5,717 (93.7)  11,154 (93.6) 540 (96.1)  
Single 405 (6.3) 383 (6.3)  766 (6.4) 22 (3.9)  
Gestational age at 
birth 
     
<0.001 
     
0.31 
<40 weeks 3,124 (49.0) 2,680 (43.9)  5,531 (46.4) 273 (48.6)  
 3,258 (51.0) 3,420 (56.1)  6,389 (53.6) 289 (51.4)  
Season at birth     0.79     0.92 
Spring or summer 2,697 (42.3) 2,592 (42.5)  5,052 (42.4) 237 (42.2)  
Autumn or winter 3,685 (57.7) 3,508 (57.5)  6,868 (57.6) 325 (57.8)  
Mode of delivery      0.23     0.35 
Vaginal 5,313 (83.2) 5,127 (84.0)  9,978 (83.7) 462 (82.2)  
Caesarean section 1,069 (16.8) 973 (16.9)  1,942 (16.3) 100 (17.8)  
Plurality      0.11     0.80 
Singleton 6,247 (97.9) 5,995 (98.3)  11,690 (98.1) 552 (98.2)  
Twin 135 (2.1) 105 (1.7)  230 (1.9) 10 (1.8)  
aFinnish growth referenceE3 






Continued Table E2 Background factors potentially associated with linear growth or with 
exposure to inhaled corticosteroids in infancy in the study population of 12,482 childen. 
 Height-for-age percentilea  Exposure to inhaled 
corticosteroids 
 
Column, count (%) <50th th p-value No Yes p-value 
Parity     <0.001     <0.001 
0 sibling 2,882 (45.2) 3,040 (49.8)  5,711 (47.9) 211 (37.4)  
 3,500 (54.8) 3,060 (50.2)  6,209 (52.1) 351 (62.6)  
Birth lengthb     <0.001     0.003 
AGA 6,109 (95.7) 5,768 (94.6)  11,354 (95.3) 523 (93.0)  
SGA 214 (3.4) 30 (0.5)  222 (1.9) 22 (3.9)  
LGA 59 (0.9) 302 (5.0)  344 (2.9) 17 (3.0)  
Birth weightb     <0.001     0.01 
AGA 6,098 (95.5) 5,837 (95.7)  11,409 (95.7) 526 (93.6)  
SGA 216 (3.4) 45 (0.7)  239 (2.0) 22 (3.9)  
LGA 68 (1.1) 218 (3.6)  272 (2.9) 14 (2.5)  
aFinnish growth referenceE3 
bFinnish birth size referenceE5 
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Abbrevations: AGA: Appropriate for gestational age; LGA: Large for gestational age; SGA: Small for gestational 
age  
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